RTW Venture Fund Limited Change of Name (9402D)
27 Junho 2023 - 3:00AM
UK Regulatory
TIDMRTW
RNS Number : 9402D
RTW Venture Fund Limited
27 June 2023
LEI: 549300Q7EXQQH6KF7Z84
27 June 2023
RTW VENTURE FUND LIMITED
(the "Company")
Change of Name
RTW Venture Fund , a London Stock Exchange-listed investment
fund focused on identifying transformative assets with high growth
potential across the life sciences sector is pleased to announce
that the Company has changed its name to RTW Biotech Opportunities
Ltd. The Guernsey registry has confirmed the name change, effective
22 June 2023.
Shareholdings will be unaffected by the change of name, and the
Company's TDIMs, ISIN and SEDOLs all remain unchanged. Existing
share certificates should be retained and will remain valid for all
purposes.
Rod Wong, Managing Partner of RTW Investments, LP, the Company's
Investment Manager commented:
"We are pleased to announce the change of the Company's name to
RTW Biotech Opportunities Ltd which better places us among our
listed healthcare and biotech investment company/trust peers and
more accurately reflects the Company's full life cycle approach to
biotech investing as a partner that can invest in both the private
and public domains and across the capital structure."
For Further Information:
RTW Investments, LP +44 (0)20 7959 6361
Woody Stileman, Managing Director
Krisha McCune, Director, Client Service
Buchanan +44 (0)20 7466 5107
Charles Ryland
Henry Wilson
George Beale
Numis +44 (0)20 7260 1000
Freddie Barnfield
Nathan Brown
Euan Brown
BofA Securities +44 (0) 20 7628 1000
Edward Peel
Kieran Millar
Cadarn Capital
David Harris +44 (0) 73 6888 3211
Elysium Fund Management Limited +44 (0) 14 8181 0100
Joanna Duquemin Nicolle, Chief Executive Officer
Sadie Morrison, Managing Director
Morgan Stanley Fund Services USA LLC +1 (914) 225 8885
About RTW Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an
investment fund focused on identifying transformative assets with
high growth potential across the biopharmaceutical and medical
technology sectors. Driven by a long-term approach to support
innovative businesses, RTW Biotech Opportunities Ltd invests in
companies developing next-generation therapies and technologies
that can significantly improve patients' lives.
RTW Biotech Opportunities Ltd is managed by RTW Investments, LP,
a leading healthcare-focused entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more
information.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CANFLFVSRIIRFIV
(END) Dow Jones Newswires
June 27, 2023 02:00 ET (06:00 GMT)
Rtw Biotech Opportunities (LSE:RTWG)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Rtw Biotech Opportunities (LSE:RTWG)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025
